- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01213680
Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease
November 13, 2013 updated by: Pharmacosmos A/S
Open-label Pharmakokinetic Study of Iron Isomaltoside 1000 (Monofer)Administered by 500 mg IV Injection or 1000 mg Intravenous Infusion to Patients With Inflammatory Bowel Disease (PK-IBD-02)
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from inflammatory bowel disease
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women, aged more than 18 years
- Subjects diagnosed with inflammatory bowel disease and mild to moderate disease activity (defined as a score of less than or equal to 5 on the Harvey-Bradshaw index for Crohn's disease and a Mayo score (subscore without endoscopy) of less than or equal to 6 for ulcerative colitis)
- Weight above 50 kg
- Hb <12 g/dL (7.45 mmol/L)
- Transferrin saturation (TfS) <20%
- Life expectancy beyond 12 months by investigator's judgment
- Willingness to participate after informed consent -
Exclusion Criteria:
- Anaemia predominantly caused by other factors than iron deficiency anaemia
- Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
- Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulphate)
- Known hypersensitivity to any excipients in the investigational drug products
- Subjects with a history of multiple allergies
- Active Intestinal Tuberculosis
- Active intestinal amoebic infections
- Decompensated liver cirrhosis and hepatitis (Alanine Aminotransferase (ALT) > 3 times upper limit normal)
- History of immunocompromise and/or history of Hepatitis B and/or C
- Acute infections (assessed by clinical judgment), supported by white blood cells (WBC) and C-reactive protein (CRP))
- Rheumatoid arthritis with symptoms or signs of active joint inflammation
- Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, intrauterine devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches)
- Extensive active bleeding necessitating blood transfusion
- Planned elective surgery during the study
- Participation in any other clinical study within 3 months prior to screening
- Untreated B12 or folate deficiency
- Other I.V. or oral iron treatment or blood transfusion within 4 weeks prior to screening visit
- Erythropoietin treatment within 4 weeks prior to screening visit
- Any other medical condition that, in the opinion of Investigator, may cause the patient to be unsuitable for the completion of the study or place the patient at potential risk from being in the study. Example: Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 500 mg iron isomaltoside 1000 as bolus injection
|
500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
|
Active Comparator: 1000 mg iron isomaltoside as intravenous infusion
|
1000 mg iron isomaltoside administered as a infusion over 15 minutes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total serum iron pharmakokinetic parameters
Time Frame: 24, 48 and72 hours
|
24, 48 and72 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total urine-iron pharmakokinetic parameters
Time Frame: 24, 48 and 72 hours
|
24, 48 and 72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
November 1, 2012
Study Registration Dates
First Submitted
October 1, 2010
First Submitted That Met QC Criteria
October 1, 2010
First Posted (Estimate)
October 4, 2010
Study Record Updates
Last Update Posted (Estimate)
November 14, 2013
Last Update Submitted That Met QC Criteria
November 13, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-Monofer-PK-IBD-02
- PK-IBD-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Disease
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Kyungpook National University HospitalDaegu Catholic University Medical Center; Yeungnam University Hospital; DongGuk...RecruitingIdiopathic Chronic Inflammatory Bowel DiseaseKorea, Republic of
-
Assiut UniversityUnknownHepatobilliary Manifestations in Inflammatory Bowel Disease Patients
Clinical Trials on Monofer (iron isomaltoside 1000)
-
Pharmacosmos A/SCompletedInflammatory Bowel DiseaseDenmark
-
Pharmacosmos A/SCompletedPatients With Chemotherapy Induced Anemia (CIA)United States
-
Pharmacosmos A/SMax NeemanCompleted
-
Pharmacosmos UK LtdBioStataCompletedIron Deficiency AnaemiaUnited Kingdom
-
Pharmacosmos A/SBioStataCompletedIron Deficiency AnemiaDenmark
-
Pharmacosmos A/SCompletedAnemia | Iron Metabolism Disorders | Deficiency Diseases | Anemia, Iron Deficiency | Hematologic DiseaseJapan
-
Universität des SaarlandesCompletedAnemia, Iron-DeficiencyGermany
-
Yonsei UniversityCompletedComplex Valvular Heart SurgeryKorea, Republic of
-
Alberta Health Services, CalgaryPharmacosmos A/SNot yet recruitingGynecologic Cancer | Surgery | Anemia, Iron Deficiency